Loading
NanoEcho was developing a way to see whether rectal cancer had spread to nearby lymph nodes, using iron oxide particles that vibrate in a magnetic field and show up on ultrasound. The company was declared bankrupt in October 2026.
NanoEcho AB (publ), of Lund, Sweden, developed a diagnostic method combining iron oxide-based nanoparticles, a magnetic field and ultrasound imaging to map whether early rectal cancer has spread to nearby lymph nodes, with the aim of sparing patients unnecessary major surgery. Its phase 2 study (NCT06693375) evaluated dose and safety of NanoEcho Particle-1 with the NanoEcho imaging device in healthy volunteers and rectal cancer patients, under EU trial number 2024-515335-29-00. On 12 October 2026 the Helsingborg District Court declared the company bankrupt and appointed a trustee. Its first registered cancer study, NCT06693375, was posted on ClinicalTrials.gov in November 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/